edison tv
Investment Companies
“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
Associated equity: AlzeCure Pharma
Edison Investment Research is terminating coverage on AlzeCure Pharma. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.
Previously published reports can still be accessed via our website.
AlzeCure Pharma — 2 videos in collection
AlzeCure Pharma is a clinical-stage biotech company based in Sweden, focused on developing its pipeline of small molecule drugs for the treatment of Alzheimer’s disease (symptomatic and disease modifying) and pain (neuropathic and osteoarthritic). It recently initiated two Phase I trials, one for ACD856, which is being developed as a symptomatic treatment for the Alzheimer’s disease, and another for ACD440, a topical treatment for neuropathic pain. In this video, Martin Jönsson, AlzeCure’s chief executive officer, provides an overview of the pipeline and outlines newsflow expected in the year ahead.
Get access to the very latest content matched to your personal investment style.